LOAD MORE
You're viewed all 17 products
Lurasidone
References
FAQ's
References
- Kakiya, Yuzo; Oda, Mayumi, Process For Producing Imide Compound, Sumitomo Pharmaceuticals Co., Ltd., Japan, EP1652848B1, February 1, 2012
- Kumar Talluri, M. V. N.; Dharavath, Shireesha; Kalariya, Pradipbhai D.; Prasanth, B.; Srinivas, R., Structural characterization of alkaline and oxidative stressed degradation products of lurasidone using LC/ESI/QTOF/MS/MS, Journal of Pharmaceutical and Biomedical Analysis Volume: 105, Pages: 1-9, 2015
Frequently Asked Questions
Can Lurasidone impurities impact its bioavailability?
Yes, impurities in Lurasidone can affect its bioavailability by altering its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion. Their control ensures consistent drug performance.
Is there ongoing research to improve impurity control in Lurasidone?
Ongoing research aims to develop more efficient analytical methods and manufacturing processes to minimize impurities in Lurasidone, ensuring it meets the highest quality and safety standards.
How are Lurasidone impurities monitored during the manufacturing process?
Manufacturers implement robust in-process controls and perform regular testing and monitoring of raw materials, intermediates, and final products to ensure impurity levels in Lurasidone are within acceptable limits.
What is the recommended storage temperature for Lurasidone impurities?
Lurasidone impurities should be stored, at a controlled room temperature, usually between 2-8 °C.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.